[go: up one dir, main page]

UY34380A - ?determinación de polimorfismos de nucleótido simple útiles para predecir la respuesta clínica al acetato de glatirámero?. - Google Patents

?determinación de polimorfismos de nucleótido simple útiles para predecir la respuesta clínica al acetato de glatirámero?.

Info

Publication number
UY34380A
UY34380A UY0001034380A UY34380A UY34380A UY 34380 A UY34380 A UY 34380A UY 0001034380 A UY0001034380 A UY 0001034380A UY 34380 A UY34380 A UY 34380A UY 34380 A UY34380 A UY 34380A
Authority
UY
Uruguay
Prior art keywords
polymorphysms
glatiramber
preach
acetate
determination
Prior art date
Application number
UY0001034380A
Other languages
English (en)
Inventor
Macciardi Fabio
Tchelet Amir
Levy Joseph
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34380A publication Critical patent/UY34380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Método para tratar un sujeto humano afectado por esclerosis múltiple o ataque clínico único consistente con esclerosis múltiple con una composición farmacéutica que comprende acetato de glatirámero, que comprende los pasos de: i. determinar un genotipo del sujeto en uno o más polimorfismos de nucleótido simple (SNP) seleccionados del grupo que consiste en los SNP descriptos en el Grupo 1, ii. identificar al sujeto como un respondedor predicho al acetato de glatirámero basándose en el genotipo determinado; y iii. administrar la composición fa rmacéutica al sujeto sólo si el sujeto se identifica como un respondedor predicho al acetato de glatirámero.
UY0001034380A 2011-10-10 2012-10-10 ?determinación de polimorfismos de nucleótido simple útiles para predecir la respuesta clínica al acetato de glatirámero?. UY34380A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161545282P 2011-10-10 2011-10-10
US201261636560P 2012-04-20 2012-04-20

Publications (1)

Publication Number Publication Date
UY34380A true UY34380A (es) 2013-05-31

Family

ID=48082342

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034380A UY34380A (es) 2011-10-10 2012-10-10 ?determinación de polimorfismos de nucleótido simple útiles para predecir la respuesta clínica al acetato de glatirámero?.

Country Status (17)

Country Link
US (2) US8815511B2 (es)
EP (1) EP2765857A4 (es)
JP (1) JP2014530819A (es)
KR (1) KR20140101730A (es)
CN (1) CN103957705A (es)
AR (1) AR088294A1 (es)
AU (1) AU2012323345A1 (es)
BR (1) BR112014008752A2 (es)
CA (1) CA2851510A1 (es)
EA (1) EA201490749A1 (es)
HK (1) HK1200274A1 (es)
IL (1) IL231723A0 (es)
MX (1) MX2014004309A (es)
TW (1) TW201326399A (es)
UY (1) UY34380A (es)
WO (1) WO2013055683A1 (es)
ZA (1) ZA201403049B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178495A1 (en) 2009-08-20 2012-03-29 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
WO2013055683A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
JP6432974B2 (ja) * 2014-06-20 2018-12-05 国立大学法人東北大学 ＴａｇＳＮＰの選択方法、選択用コンピュータシステム、及び、選択用ソフトウエア
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016172124A1 (en) * 2015-04-21 2016-10-27 Teva Pharmaceutical Industries Ltd. Select single nucleotide polymorphisms predictive of response to glatiramer acetate
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
LT3506921T (lt) 2016-08-31 2023-08-10 Mapi Pharma Ltd Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US11396825B2 (en) * 2017-08-14 2022-07-26 General Electric Company Turbine diagnostic feature selection system
EP3874455A4 (en) * 2018-11-01 2022-08-03 I2Dx, Inc. INTELLIGENT SYSTEM AND METHODS FOR THERAPEUTIC TARGET IDENTIFICATION
CA3141888A1 (en) * 2019-05-30 2020-12-03 The University Of Newcastle A method of treatment or prophylaxis

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL140592A0 (en) 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
HU229720B1 (en) 1998-09-25 2014-05-28 Yeda Res & Dev Copolymer 1 related polypeptides for us as molecular weight markers and for therapeutic use
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU6281599A (en) 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
EP1128839A4 (en) 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
HK1054507B (zh) 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
JP2003522799A (ja) 2000-02-18 2003-07-29 イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス コポリマー１の経口、経鼻および経肺投与製剤
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL153236A0 (en) 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL150801A0 (en) 2000-06-07 2003-02-12 Yeda Res & Dev The use of copolymer 1 and related peptides and polypeptides for protecting central nervous system cells from glutamate toxicity
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
MXPA04005433A (es) 2001-12-04 2004-10-11 Teva Pharma Proceso para la medicion de la potencia de acetato de glatiramero.
RU2303996C2 (ru) 2001-12-06 2007-08-10 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Вакцина и способ лечения болезней двигательных нейронов
US20060019269A1 (en) 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US20080293750A1 (en) 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
WO2005075022A2 (en) 2004-01-30 2005-08-18 Decode Genetics Ehf. Susceptibility gene for myocardial infraction, stroke, and paod; methods of treatment
WO2004043995A2 (en) 2002-11-13 2004-05-27 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
AU2004203772B2 (en) 2003-01-07 2009-07-16 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
AU2004206120B2 (en) 2003-01-21 2009-09-24 Yeda Research And Development Co. Ltd. COP 1 for treatment of inflammatory bowel diseases
CA2518079A1 (en) 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
ES2466390T3 (es) 2003-05-14 2014-06-10 Teva Pharmaceutical Industries Limited Terapia de combinación con acetato de glatiramer y mitoxantrona para el tratamiento de la esclerosis múltiple
US20050064483A1 (en) 2003-08-28 2005-03-24 Baylor College Of Medicine Gene expression profiling technology for treatment evaluation of multiple sclerosis
KR20060090715A (ko) 2003-09-29 2006-08-14 추가이 세이야쿠 가부시키가이샤 Ｎｋ 세포에 발현하는 단백질
EP1680087A1 (en) 2003-10-31 2006-07-19 Teva Pharmaceutical Industries Limited Nanoparticles for drug delivery
EP1684797A1 (en) 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
US20100216863A1 (en) 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US20050266432A1 (en) * 2004-02-26 2005-12-01 Illumina, Inc. Haplotype markers for diagnosing susceptibility to immunological conditions
WO2005084377A2 (en) 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US20050266410A1 (en) 2004-05-19 2005-12-01 Emily Walsh Methods of Human Leukocyte Antigen typing by neighboring single nucleotide polymorphism haplotypes
MXPA06015096A (es) * 2004-06-25 2007-05-09 Id Biomedical Corp Quebec Composiciones y metodos para el tratamiento de trastornos neurologicos.
WO2006029036A2 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
AU2005282249B2 (en) 2004-09-09 2012-08-02 Teva Pharmaceutical Industries, Ltd. Process for preparation of mixtures of polypeptides using purified hydrobromic acid
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2006050122A1 (en) 2004-10-29 2006-05-11 Sandoz Ag Processes for preparing glatiramer
EP1838326A4 (en) 2005-02-02 2009-09-30 Teva Pharma PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
PT1848415E (pt) 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
US20060240463A1 (en) 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007030573A2 (en) 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
WO2007081975A2 (en) 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
US20080021192A1 (en) 2006-07-05 2008-01-24 Momenta Pharmaceuticals, Inc. Process for the preparation of copolymer-1
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US7795033B2 (en) 2007-03-19 2010-09-14 The United States Of America As Represented By The Department Of Health And Human Services Methods to predict the outcome of treatment with antidepressant medication
BRPI0819001A2 (pt) 2007-11-28 2014-10-07 Teva Pharma "método para retardar o acesso de esclerose múltipla clinicamente defenitiva em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão da atividade de doença monitorada por imagem latente de ressonância magnética (mri) em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão dos sintomas de esclerose múltipla definitiva em um paciente, método para reduzir a freqüência de recidiva em um paciente que experimentou um ataque clínico simples sugestivo de esclerose múltipla e que tem pelo menos uma lesão sugestiva de esclerose múltipla, método para retardar a progressão para a esclerose múltipla clinicamente definitiva em um paciente que apresenta um primeiro evento clínico sugestivo de esclerose múltipla e pelo menos uma lesão sugestiva de esclerose múltipla, uso de acetato de glatiramer e acetato de glatiramer
US20090177487A1 (en) 2008-01-07 2009-07-09 Tera Eerkes Methods for Assessing Genetic Compatibility
US20110158979A1 (en) 2008-06-13 2011-06-30 Prognomix, Inc. Genetic component of complications in type 2 diabetes
EP2310533A4 (en) 2008-07-04 2012-03-14 Axial Biotech Inc GENETIC MARKERS ASSOCIATED WITH DEGENERATIVE DISC DISEASE AND USES THEREOF
WO2010103292A2 (en) * 2009-03-12 2010-09-16 Brainco Biopharma S.L. A genotyping tool for improving the prognostic and clinical management of ms patients
WO2010118210A1 (en) 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US20110060279A1 (en) 2009-07-15 2011-03-10 Ayelet Altman Reduced Volume Formulation of Glatiramer Acetate and Methods of Administration
SG178495A1 (en) 2009-08-20 2012-03-29 Yeda Res & Dev Low frequency glatiramer acetate therapy
WO2011043823A2 (en) 2009-10-09 2011-04-14 Georgetown University Polypeptides that home to atherosclerotic plaque
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
WO2013055683A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
CA2895359A1 (en) 2012-12-21 2014-06-26 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate
MX2015007794A (es) 2012-12-21 2015-09-04 Teva Pharma Suministro transmucosal de acetato de glatiramer mediante parches orales.
CA2896957A1 (en) 2013-01-04 2014-07-10 Teva Pharmaceutical Industries Ltd. Characterizing a glatiramer acetate related drug product
JP2016512552A (ja) 2013-03-12 2016-04-28 テバ ファーマシューティカル インダストリーズ リミティド リツキシマブ導入療法とその後の酢酸グラチラマー療法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product

Also Published As

Publication number Publication date
BR112014008752A2 (pt) 2017-04-25
MX2014004309A (es) 2015-07-06
ZA201403049B (en) 2015-09-30
NZ624258A (en) 2016-09-30
US8815511B2 (en) 2014-08-26
KR20140101730A (ko) 2014-08-20
US20130123189A1 (en) 2013-05-16
HK1200274A1 (en) 2015-08-07
EA201490749A1 (ru) 2014-09-30
WO2013055683A1 (en) 2013-04-18
IL231723A0 (en) 2014-05-28
TW201326399A (zh) 2013-07-01
AR088294A1 (es) 2014-05-21
US9499868B2 (en) 2016-11-22
EP2765857A4 (en) 2015-12-09
CN103957705A (zh) 2014-07-30
JP2014530819A (ja) 2014-11-20
AU2012323345A1 (en) 2014-05-22
EP2765857A1 (en) 2014-08-20
US20150045306A1 (en) 2015-02-12
CA2851510A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
UY34380A (es) ?determinación de polimorfismos de nucleótido simple útiles para predecir la respuesta clínica al acetato de glatirámero?.
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
IL261563A (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
MX2020009401A (es) Ligadores de nucleótidos modificados.
CL2014000096A1 (es) Genes y proteinas para la sintesis de alcanoyl-coa
HUE052485T2 (hu) RNA készítmény immunterápiára
PL2852671T3 (pl) Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna
SMT201600375B (it) Procedimento per la produzione di estetrolo
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
DK2487659T3 (da) System til karakterisering af chaufførers kørestil
EP3044228A4 (en) Highly efficient synthesis of long rna using reverse direction approach
HRP20190057T1 (hr) Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih
BR112015003041A2 (pt) Intermediário para síntese de 1-(2-desóxi-2-fluoro-4 -tio-\beta-d-arabinofuranosil)citosina , intermediário para síntese de tionucleosídeo , e métodos para produzir estes intermediários
WO2013165921A3 (en) Therapeutic use of chardonnay seed products
CR20130539A (es) Triazolopiridinas
HRP20181874T1 (hr) Anti-cxcr3 protutijela
PT2736340T (pt) Biocontrolo de nemátodos
EP2909321A4 (en) PREPARATION OF STABLE NON-POLYADENYLATED RNAS
EP2799420A4 (en) PROCESS FOR SYNTHESIS OF 2,7-DIMETHYL-2,4,6-OCTATRIENE-1,8-DIALDEHYDE
EP2609107C0 (en) PROCESS FOR THE SYNTHESIS OF OLIGORIBONUCLEOTIDES
IL241245A (en) Bicyclo [2.2.1] acid gpr120 modulators
BR112014001556A2 (pt) modulação quimiocina seletiva de tumores
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
FR2959228B1 (fr) Nucleotides modifies
UY34552A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020